CFGI’s Capital Markets team supported Olema Pharmaceuticals (Nasdaq: OLMA) with an initial public offering of 11,000,000 shares of common stock priced at $19.00 per share for gross proceeds of $209 million before deducting underwriting discounts, commissions and offering expenses.
The offering granted underwriters a 30-day option to purchase an additional 1,650,000 shares at the initial offering price. The shares began trading November 19, 2020, and the offering closed on November 23, 2020. For more information on the offering, please read Olema’s press release.
Olema Pharmaceuticals, Inc. (Olema Oncology) is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader. It is currently being evaluated as a single agent in an ongoing phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive, human epidermal growth factor receptor 2 negative breast cancer.
The CFGI team was led by April Coleman (Capital Markets), Chris Brandes (Capital Markets) and Michael Russo (Accounting Advisory).